Want to see SYRE full AI Analyst Report?

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

582 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SYRE Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Spyre

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SYRE Stock 12 Month Forecast

Average Price Target

$122.23

▲(13.85% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Spyre Therapeutics in the last 3 months. The average price target is $122.23 with a high forecast of $130.00 and a low forecast of $110.00. The average price target represents a 13.85% change from the last price of $107.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","44":"$44","73":"$73","102":"$102","131":"$131"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122.23076923076923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$122.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,44,73,102,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.93,93.0123076923077,96.0946153846154,99.17692307692309,102.25923076923077,105.34153846153846,108.42384615384616,111.50615384615385,114.58846153846154,117.67076923076922,120.75307692307692,123.83538461538461,126.9176923076923,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.93,92.41467455621303,94.89934911242604,97.38402366863906,99.86869822485207,102.35337278106509,104.83804733727811,107.32272189349112,109.80739644970414,112.29207100591717,114.77674556213017,117.2614201183432,119.74609467455622,{"y":122.23076923076923,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.93,91.47384615384615,93.01769230769231,94.56153846153846,96.10538461538462,97.64923076923077,99.19307692307693,100.73692307692308,102.28076923076924,103.82461538461538,105.36846153846155,106.91230769230769,108.45615384615385,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.33,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.93,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$122.23

Lowest Price Target$110.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alice Nettleton

UBS

$120

Buy

11.77%

Upside

Initiated

10/12/26

Spyre Therapeutics (SYRE) Receives a Buy from UBS

Yanan Zhu

Wells Fargo

$115

Buy

7.12%

Upside

Reiterated

10/02/26

Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

Debanjana Chatterjee

JonesTrading

$121→$130

Buy

21.09%

Upside

Assigned

10/01/26

Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (NASDAQ: SYRE), Sanofi (Other OTC: SNYNF) and Nektar Therapeutics (NASDAQ: NKTR)

Hardik Parikh

J.P. Morgan

$110

Buy

2.46%

Upside

Initiated

10/01/26

Spyre Therapeutics initiated with an Overweight at JPMorganSpyre Therapeutics initiated with an Overweight at JPMorgan

Thomas Smith

Leerink Partners

$124→$128

Buy

19.23%

Upside

Assigned

09/10/26

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

David Nierengarten

Wedbush

$123

Buy

14.57%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash Tewari

Jefferies

$98→$126

Buy

17.36%

Upside

Reiterated

09/09/26

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), United Therapeutics (NASDAQ: UTHR) and Spyre Therapeutics (NASDAQ: SYRE)

Sam Slutsky

LifeSci Capital

$116

Buy

8.05%

Upside

Reiterated

09/08/26

Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Julian Harrison

BTIG

$132→$121

Buy

12.70%

Upside

Assigned

08/26/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Spyre Therapeutics (NASDAQ: SYRE) and Summit Therapeutics (NASDAQ: SMMT)

Yatin Suneja

Guggenheim

$130

Buy

21.09%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)

David Hoang

Deutsche Bank

$135→$127

Buy

18.29%

Upside

Reiterated

08/26/26

Spyre Therapeutics price target lowered to $127 from $135 at Deutsche BankSpyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank

Alex Thompson CFA

Stifel Nicolaus

$123

Buy

14.57%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)

Colleen M. Kusy

Robert W. Baird

$90→$120

Buy

11.77%

Upside

Reiterated

08/05/26

Spyre Therapeutics price target raised to $120 from $90 at BairdSpyre Therapeutics price target raised to $120 from $90 at Baird

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/28/26

Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchSpyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

06/23/26

Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alice Nettleton

UBS

$120

Buy

11.77%

Upside

Initiated

10/12/26

Spyre Therapeutics (SYRE) Receives a Buy from UBS

Yanan Zhu

Wells Fargo

$115

Buy

7.12%

Upside

Reiterated

10/02/26

Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

Debanjana Chatterjee

JonesTrading

$121→$130

Buy

21.09%

Upside

Assigned

10/01/26

Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (NASDAQ: SYRE), Sanofi (Other OTC: SNYNF) and Nektar Therapeutics (NASDAQ: NKTR)

Hardik Parikh

J.P. Morgan

$110

Buy

2.46%

Upside

Initiated

10/01/26

Spyre Therapeutics initiated with an Overweight at JPMorganSpyre Therapeutics initiated with an Overweight at JPMorgan

Thomas Smith

Leerink Partners

$124→$128

Buy

19.23%

Upside

Assigned

09/10/26

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

David Nierengarten

Wedbush

$123

Buy

14.57%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash Tewari

Jefferies

$98→$126

Buy

17.36%

Upside

Reiterated

09/09/26

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), United Therapeutics (NASDAQ: UTHR) and Spyre Therapeutics (NASDAQ: SYRE)

Sam Slutsky

LifeSci Capital

$116

Buy

8.05%

Upside

Reiterated

09/08/26

Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Julian Harrison

BTIG

$132→$121

Buy

12.70%

Upside

Assigned

08/26/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Spyre Therapeutics (NASDAQ: SYRE) and Summit Therapeutics (NASDAQ: SMMT)

Yatin Suneja

Guggenheim

$130

Buy

21.09%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)

David Hoang

Deutsche Bank

$135→$127

Buy

18.29%

Upside

Reiterated

08/26/26

Spyre Therapeutics price target lowered to $127 from $135 at Deutsche BankSpyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank

Alex Thompson CFA

Stifel Nicolaus

$123

Buy

14.57%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)

Colleen M. Kusy

Robert W. Baird

$90→$120

Buy

11.77%

Upside

Reiterated

08/05/26

Spyre Therapeutics price target raised to $120 from $90 at BairdSpyre Therapeutics price target raised to $120 from $90 at Baird

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

07/28/26

Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchSpyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

06/23/26

Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AXGNAxoGen

MDWDMediwound

OCULOcular Therapeutix

OVIDOvid Therapeutics

ZYMEZymeworks

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Spyre Therapeutics

3 Months

Debanjana ChatterjeeJonesTrading

Success Rate

7/10 ratings generated profit

Average Return

+35.59%

Copying Debanjana Chatterjee's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +35.59% per trade.

1 Year

Alex Thompson CFAStifel Nicolaus

Success Rate

12/16 ratings generated profit

Average Return

+94.37%

Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +94.37% per trade.

2 Years

Tyler Van BurenTD Cowen

Success Rate

14/15 ratings generated profit

Average Return

+197.89%

Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +197.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYRE Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SYRE has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SYRE average Analyst price target in the past 3 months is 122.23.

Each month's total comprises the sum of three months' worth of ratings.

SYRE Financial Forecast

SYRE Earnings Forecast

Next quarter’s earnings estimate for SYRE is -$0.78 with a range of -$0.93 to -$0.57. The previous quarter’s EPS was -$0.36. SYRE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Sales Forecast

Next quarter’s sales forecast for SYRE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SYRE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Stock Forecast FAQ

What is SYRE’s average 12-month price target, according to analysts?

Based on analyst ratings, Spyre Therapeutics’s 12-month average price target is 122.23.

What is SYRE’s upside potential, based on the analysts’ average price target?

Spyre Therapeutics has 13.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SYRE a Buy, Sell or Hold?

Spyre Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Spyre Therapeutics’s price target?

The average price target for Spyre Therapeutics is 122.23. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $110.00. The average price target represents 13.85% Increase from the current price of $107.36.

What do analysts say about Spyre Therapeutics?

Spyre Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of SYRE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

SYRE Analyst Ratings

SYRE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Spyre Therapeutics

SYRE Analyst Recommendation Trends

SYRE Financial Forecast

SYRE Earnings Forecast

SYRE Sales Forecast

SYRE Stock Forecast FAQ

Detailed List of Analyst Forecasts